Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has shared an update.
Lepu Biopharma Co., Ltd. has announced the convening of its Second 2025 Extraordinary General Meeting (EGM) to discuss and potentially approve a series of resolutions related to its Restricted Share Unit (RSU) Scheme. The resolutions include the adoption of the RSU Scheme, setting a Scheme Mandate Limit for issuing new shares, and amending the company’s Articles of Association to reflect changes in the total number of issued shares. These measures are aimed at enhancing the company’s equity incentive mechanisms, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (HK:2157) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on developing and commercializing innovative therapeutics, particularly in the field of oncology, to address unmet medical needs and improve patient outcomes.
Average Trading Volume: 14,937,493
Technical Sentiment Signal: Hold
Current Market Cap: HK$10.71B
See more data about 2157 stock on TipRanks’ Stock Analysis page.